Explore AstraZeneca's recent Form 6-K detailing CEO Pascal Soriot's transfer of 136,537 shares as a gift. Discover the implications for shareholder dynamics and regulatory compliance.
Explore AstraZeneca's Q3 2025 financial performance highlighting an 11% revenue growth, improved margins, and a strong pipeline. A must-read for investors!
Explore Vertex Pharmaceuticals' Q3 2025 report, showcasing $3.1B in revenues, $1.08B net income, and a robust growth strategy. Ideal for investors seeking biotech opportunities.
AstraZeneca's 6-K filing details the approval of new articles of association, enhancing capital access. Key voting results and future trading updates included.
Discover Vertex Pharmaceuticals' 8-K filing dated November 3, 2025, detailing significant corporate changes and SEC compliance. Stay informed on VRTX's latest developments.
Discover Biogen Inc.'s latest 8-K filing detailing significant events on October 30, 2025. Stay informed on stock performance and company developments.
Discover AstraZeneca's latest Form 6-K report on Euan Ashley's director appointment at DexCom. Key insights on governance and compliance included.
AstraZeneca's Koselugo gains European approval for adults with NF1, showing 20% efficacy in trials. This marks a significant step in addressing rare disease treatment needs.
Discover Regeneron Pharmaceuticals' Q3 2025 financial performance, highlighting revenue growth, net income rise, and R&D investments amid litigation risks. A must-read for investors!
Explore Regeneron Pharmaceuticals' 8-K filing from October 28, 2025, detailing crucial updates. Learn more about stock performance and regulatory compliance.
Discover AstraZeneca's latest financial report detailing Saphnelo's positive CHMP review for SLE treatment, trial insights, and future growth potential in autoimmune diseases.
AstraZeneca's historic agreement with the U.S. government aims to lower drug prices by up to 80%. The deal includes a $50 billion investment in U.S. manufacturing and R&D, enhancing patient access.